These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23064166)

  • 1. Incidence of hepatotoxicity of highly active antiretroviral therapy in a tertiary health centre in Nigeria.
    Ugiagbe RA; Malu AO; Bojuwoye BJ; Onunu AN
    Niger Postgrad Med J; 2012 Sep; 19(3):127-32. PubMed ID: 23064166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Period of onset and lack of clinical manifestation of hepatotoxicity after commencing highly active antiretroviral therapy.
    Ugiagbe RA; Ugiagbe EE
    Niger J Clin Pract; 2012; 15(1):63-7. PubMed ID: 22437093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
    Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
    Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HAART and liver: is it safe?
    Antonello VS; Kliemann DA; Rigel Santos B; Tovo CV
    J Infect Dev Ctries; 2014 Nov; 8(11):1444-50. PubMed ID: 25390056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
    Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
    Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity of antiretroviral therapy.
    Kontorinis N; Dieterich D
    AIDS Rev; 2003; 5(1):36-43. PubMed ID: 12875106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy.
    Rajesh R; Vidyasagar S; Varma DM; Mohiuddin S; Noorunnisa
    Int J Risk Saf Med; 2011; 23(3):171-80. PubMed ID: 22020397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver aminotransferases in under-five HIV-positive children on HAART.
    Ajulo MO; Omole MK; Moody JO; Dixon-Umo OT; Salami OL
    Afr J Med Med Sci; 2015 Sep; 44(3):197-204. PubMed ID: 27280231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardio-vascular diseases among highly active antiretroviral therapy (HAART) treated HIV seropositive volunteers at a treatment centre in Lagos, Nigeria.
    Ekun OA; Fasela EO; Oladele DA; Liboro GO; Raheem TY
    Pan Afr Med J; 2021; 38():206. PubMed ID: 33995812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and risk factors for distal sensory polyneuropathy in HIV infection in a developing country.
    Ekenze OS; Nwosu CM; Ogunniyi A
    Int J STD AIDS; 2014 Mar; 25(3):178-83. PubMed ID: 23970649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.
    Núñez M
    Hepatology; 2010 Sep; 52(3):1143-55. PubMed ID: 20812358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.